Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nebraska ephedrine law exempts new Primatene Tablets, Bronkaid Dual Action.

This article was originally published in The Tan Sheet

Executive Summary

NEBRASKA EPHEDRINE LAW EXEMPTS NEW PRIMATENE TABLETS, BRONKAID DUAL ACTION from the controlled substance requirements established as of July 19 for most ephedrine-containing products sold in the state ("The Tan Sheet" July 29, In Brief). The law specifically exempts combination products with 12.5-25 mg ephedrine and 200-400 mg guaifenesin.

You may also be interested in...



Ephedra Product Liability Coverage Now Offered By Fewer Than 10 Insurers

Between five and 10 product liability companies have stopped offering coverage for ephedra alkaloid-containing products since June, when HHS Secretary Tommy Thompson issued a statement on ephedra's safety

Ephedra Product Liability Coverage Now Offered By Fewer Than 10 Insurers

Between five and 10 product liability companies have stopped offering coverage for ephedra alkaloid-containing products since June, when HHS Secretary Tommy Thompson issued a statement on ephedra's safety

Ephedra Product Liability Coverage Now Offered By Fewer Than 10 Insurers

Between five and 10 product liability companies have stopped offering coverage for ephedra alkaloid-containing products since June, when HHS Secretary Tommy Thompson issued a statement on ephedra's safety

Topics

UsernamePublicRestriction

Register

PS085888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel